A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer

A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer

Background. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality tre...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Avgustinovich, S. G. Afanasyev, L. V. Spirina, E. V. Kaygorodova, R. V. Ermolenko, E. N. Samtsov, I. G. Frolova, O. V. Cheremisina
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2024-03-01
Series:	Сибирский онкологический журнал
Subjects:	gastric cancer her2/neu overexpression combined modality treatment neoadjuvant therapy complete tumor regression
Online Access:	https://www.siboncoj.ru/jour/article/view/2970
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NEW INDICATORS OF HSP27 FUNCTIONAL STATE IN BREAST CANCER CELLS WITH DIFFERENT VARIANTS OF HER2/NEU-STATUS
by: E. V. Kaigorodova, et al.
Published: (2016-02-01)

An Immunohistochemical Study in Urothelial Carcinoma of HER2/neu in Iraqi Patients
by: Athraa Falah Alshimerry
Published: (2025-01-01)

Prognostic value of immunohistochemical marker HER2/neu in patients resected for gastric cancer stage IIIA
by: O. M. Levyk
Published: (2014-04-01)

Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
by: Taha Heba F., et al.
Published: (2021-05-01)

Expression of Human Epidermal Growth Factor Receptor (HER2/neu) and Proliferative Marker Ki-67 in Nonneoplastic, Preneoplastic, Neoplastic Lesions of Gallbladder and Its Association with Clinicopathological Parameters
by: Kiran Yadav, et al.
Published: (2025-01-01)

Comparative evaluation of the prognostic significance of molecular tumor markers (estrogen and progesterone receptors, HER-2/neu) and the Nottingham prognostic index in breast cancer
by: V. Sekhri, et al.
Published: (2024-02-01)

Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry
by: Saiqa Nisar, et al.
Published: (2024-10-01)

EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)
by: O. D. Bragina, et al.
Published: (2021-10-01)

Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3
by: O. D. Bragina, et al.
Published: (2023-01-01)

Toxoplasma gondii destroys Her2/Neu-expressing mammary cancer cells in vitro using a continuous feed medium approach
by: Esra Atalay Şahar, et al.
Published: (2020-10-01)

Assessing functional suitability of a lyophilized formulation containing designed ankyrin repeat proteins for radionuclide imaging of HER2/neu overexpression in malignant tumors
by: R. N. Varvashenya, et al.
Published: (2024-10-01)

Hubungan Overekspresi HER-2/neu dengan Status Reseptor Hormonal dan Grading Histopatologi pada Penderita Karsinoma Payudara di RS Onkologi Surabaya
by: JACOBUS OCTOVIANUS, et al.
Published: (2012-08-01)

The development of a highly specific radiochemical compound based on labeled 99mtc recombinant molecules for targeted imaging of cells with the overexpression of Her-2 / neu
by: Olga D. Bragina, et al.
Published: (2017-10-01)

Hubungan Faktor Usia dengan Grading Histopatologi, Status Reseptor Hormonal, dan Ekspresi HER-2/neu pada Penderita Karsinoma Payudara di Rumah Sakit Onkologi Surabaya
by: JACOBUS OCTOVIANUS, et al.
Published: (2012-01-01)

Immunohistochemical Study of Ki-67 and HER2/neu and its Correlation with Clinicopathological Features in Surface Epithelial Tumors of the Ovary
by: Sameeksha Alva, et al.
Published: (2025-01-01)

Colorectal Carcinoma: Is There Any Correlation between Her2/neu Expression, Ki-67 Score, and Tumor Budding and Clinicopathological Parameters?—A Prospective Institution-Based Study
by: Susnata Khan, et al.
Published: (2024-10-01)

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2025-03-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
by: O. D. Bragina, et al.
Published: (2022-10-01)

A comparative study of hormone receptors and HER2NEU receptor status in premenopausal and postmenopausal women with breast carcinoma in a tertiary care hospital of North-East India
by: Shriya Roy, et al.
Published: (2025-03-01)

Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
by: O. D. Bragina, et al.
Published: (2021-04-01)

EFFICACY OF COMBINED MODALITY TREATMENT INCLUDING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER
by: Yu. V. Rudyk, et al.
Published: (2016-02-01)

A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer
by: O. D. Bragina, et al.
Published: (2023-10-01)

Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer
by: O. D. Bragina, et al.
Published: (2021-06-01)

Immediate results of neoadjuvant chemotherapy for resectable colon cancer
by: D. I. Azovsky, et al.
Published: (2025-03-01)

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2025-03-01)

Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer
by: Yuwen Liang, et al.
Published: (2025-06-01)

Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters Expressão imunoistoquímica dos marcadores Ki-67, neun, sinaptofisina, p53 e HER2 em meduloblastoma e sua correlação com os parâmetros clínico-patológicos
by: Rosalva Thereza Meurer, et al.
Published: (2008-06-01)

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
by: Sedat Yıldırım, et al.
Published: (2025-05-01)

Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status
by: Yongtao Li, et al.
Published: (2025-06-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

LONG-LASTING CONTROL OF HER-2 POSITIVE DISSEMINATED BREAST CANCER IN A REPRODUCTIVE AGED PATIENT
by: A. V. Vazhenin, et al.
Published: (2021-06-01)

Developing a predictive model for neoadjuvant therapy in HER2 overexpression breast cancer using multi-parameter MRI radiomics: two-center retrospective study
by: Lingling Wang, et al.
Published: (2025-07-01)

A Mathematical Model for Complete Morphological Regression in Primary Operable HER2-Positive Breast Cancer
by: A. E. Orlov, et al.
Published: (2021-04-01)

Inactivation of the CMAH gene and deficiency of Neu5Gc play a role in human brain evolution
by: Yuxin Liu, et al.
Published: (2025-02-01)

Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
by: Manlu Cui, et al.
Published: (2024-10-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
by: A. V. Avgustinovich, et al.
Published: (2022-03-01)

Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: a retrospective cohort study
by: Shuai Yang, et al.
Published: (2025-03-01)

Immunohistochemical characteristics of breast cancer, increasing the risk of local reccurence after organosaving treatment
by: S. M. Demidov, et al.
Published: (2018-10-01)